{"title":"SFJ制药公司将开展辉瑞达科米替尼治疗一线晚期NSCLC的III期临床试验","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I9.1809","DOIUrl":null,"url":null,"abstract":"SFJ Pharmaceuticals has formed its second collaborative development agreement with Pfizer, this time to conduct a Phase III trial to evaluate Pfizer’s pan-Her (pan-human epidermal growth factor receptor) inhibitor dacomitinib (PF-00299804) as a first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with activating EGFR (epidermal growth factor receptor) mutations. The NSCLC market continues to move towards molecular-targeted therapies used alongside companion diagnostics to guide treatment decisions.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"7 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"SFJ Pharmaceuticals to Conduct Phase III Trial of Pfizer’s Dacomitinib in First-Line Advanced NSCLC\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I9.1809\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"SFJ Pharmaceuticals has formed its second collaborative development agreement with Pfizer, this time to conduct a Phase III trial to evaluate Pfizer’s pan-Her (pan-human epidermal growth factor receptor) inhibitor dacomitinib (PF-00299804) as a first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with activating EGFR (epidermal growth factor receptor) mutations. The NSCLC market continues to move towards molecular-targeted therapies used alongside companion diagnostics to guide treatment decisions.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"7 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I9.1809\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I9.1809","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
SFJ Pharmaceuticals to Conduct Phase III Trial of Pfizer’s Dacomitinib in First-Line Advanced NSCLC
SFJ Pharmaceuticals has formed its second collaborative development agreement with Pfizer, this time to conduct a Phase III trial to evaluate Pfizer’s pan-Her (pan-human epidermal growth factor receptor) inhibitor dacomitinib (PF-00299804) as a first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with activating EGFR (epidermal growth factor receptor) mutations. The NSCLC market continues to move towards molecular-targeted therapies used alongside companion diagnostics to guide treatment decisions.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
